[{"orgOrder":0,"company":"Elutia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Rifampicin","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Elutia","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Elutia \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Elutia \/ Not Applicable"},{"orgOrder":0,"company":"Elutia","sponsor":"Berkeley Biologics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Divestment","leadProduct":"Rifampicin","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Elutia","amount2":0.040000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.040000000000000001,"dosageForm":"Implant","sponsorNew":"Elutia \/ Berkeley Biologics","highestDevelopmentStatusID":"4","companyTruncated":"Elutia \/ Berkeley Biologics"},{"orgOrder":0,"company":"Elutia","sponsor":"HighCape Capital","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Private Placement","leadProduct":"Rifampicin","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Elutia","amount2":0.029999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.029999999999999999,"dosageForm":"Implant","sponsorNew":"Elutia \/ HighCape Capital","highestDevelopmentStatusID":"4","companyTruncated":"Elutia \/ HighCape Capital"},{"orgOrder":0,"company":"Elutia","sponsor":"Berkeley Biologics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Divestment","leadProduct":"Rifampicin","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Elutia","amount2":0.040000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.040000000000000001,"dosageForm":"Implant","sponsorNew":"Elutia \/ Berkeley Biologics","highestDevelopmentStatusID":"4","companyTruncated":"Elutia \/ Berkeley Biologics"}]

Find Clinical Drug Pipeline Developments & Deals by Elutia

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
filter

Year

filter

DEALS // DEV.

filter

Country

filter
Sponsor
filter

Therapeutic Area

filter

Study Phase

filter

Deal Type

filter

Product Type

filter

Dosage Form

filter

Lead Product

filter

Target

Therapeutic Area by Lead Product

ForexGraph

Study Phase by Lead Product

ForexGraph

Company by Lead Product

ForexGraph

Top Deals by Deal Size (USD bn)

ForexGraph

01

BIO Partnering at JPM
Not Confirmed
BIO Partnering at JPM
Not Confirmed

Details : Through the divestment, Elutia sells its Orthobiologics business unit to Berkeley Biologics, including Company’s lead drug-eluting product, CanGaroo featuring an advanced biomatrix and the drugs rifampin and minocycline for extended antibiotic protecti...

Brand Name : CanGaroo RM

Molecule Type : Small molecule

Upfront Cash : $35.0 million

November 09, 2023

Lead Product(s) : Rifampicin,Minocycline Hydrochloride

Therapeutic Area : Infections and Infectious Diseases

Highest Development Status : Preclinical

Sponsor : Berkeley Biologics

Deal Size : $35.0 million

Deal Type : Divestment

blank

02

BIO Partnering at JPM
Not Confirmed
BIO Partnering at JPM
Not Confirmed

Details : The net proceeds will support the Company’s advancement of its drug-eluting biomatrix products, including CanGaroo featuring an advanced biomatrix and the drugs rifampin and minocycline for extended antibiotic protection.

Brand Name : CanGaroo

Molecule Type : Small molecule

Upfront Cash : Undisclosed

September 19, 2023

Lead Product(s) : Rifampicin,Minocycline Hydrochloride

Therapeutic Area : Infections and Infectious Diseases

Highest Development Status : Preclinical

Sponsor : HighCape Capital

Deal Size : $26.2 million

Deal Type : Private Placement

blank

03

BIO Partnering at JPM
Not Confirmed
BIO Partnering at JPM
Not Confirmed

Details : Through the divestment, Elutia sells its Orthobiologics business unit to Berkeley Biologics, including Company’s lead drug-eluting product, CanGaroo featuring an advanced biomatrix and the drugs rifampin and minocycline for extended antibiotic protecti...

Brand Name : CanGaroo

Molecule Type : Small molecule

Upfront Cash : $35.0 million

September 18, 2023

Lead Product(s) : Rifampicin,Minocycline Hydrochloride

Therapeutic Area : Infections and Infectious Diseases

Highest Development Status : Preclinical

Sponsor : Berkeley Biologics

Deal Size : $35.0 million

Deal Type : Divestment

blank

04

BIO Partnering at JPM
Not Confirmed
BIO Partnering at JPM
Not Confirmed

Details : CanGaroo RM Antibacterial Envelope contains the antibiotics rifampin and minocycline, which have been shown in preclinical testing to reduce bacterial colonization on the envelope.

Brand Name : CanGaroo

Molecule Type : Small molecule

Upfront Cash : Not Applicable

March 20, 2023

Lead Product(s) : Rifampicin,Minocycline Hydrochloride

Therapeutic Area : Infections and Infectious Diseases

Highest Development Status : Preclinical

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank